Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate SELLAS Life Sciences Group, Inc. before investing.

In this article, we go over a few key elements for understanding SELLAS Life Sciences Group, Inc.’s stock price such as:

• SELLAS Life Sciences Group, Inc.’s current stock price and volume
• Why SELLAS Life Sciences Group, Inc.’s stock price changed recently
• Upgrades and downgrades for SLS from analysts
• SLS’s stock price momentum as measured by its relative strength

About SELLAS Life Sciences Group, Inc. (SLS)

Before we jump into SELLAS Life Sciences Group, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Want to learn more about SELLAS Life Sciences Group, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about SELLAS Life Sciences Group, Inc..

SELLAS Life Sciences Group, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, SELLAS Life Sciences Group, Inc.’s stock price was $1.620.

SELLAS Life Sciences Group, Inc. is up 10.96% from its previous closing price of $1.460.

During the last market session, SELLAS Life Sciences Group, Inc.’s stock traded between $1.465 and $1.640. Currently, there are approximately 108.40 million shares outstanding for SELLAS Life Sciences Group, Inc..

SELLAS Life Sciences Group, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

SELLAS Life Sciences Group, Inc. Stock Price History

SELLAS Life Sciences Group, Inc.’s (SLS) price is currently down 10.99% so far this month.

During the month of November, SELLAS Life Sciences Group, Inc.’s stock price has reached a high of $1.850 and a low of $1.390.

Over the last year, SELLAS Life Sciences Group, Inc. has hit prices as high as $2.480 and as low as $0.772. Year to date, SELLAS Life Sciences Group, Inc.’s stock is up 55.77%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused SELLAS Life Sciences Group, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded SELLAS Life Sciences Group, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate SELLAS Life Sciences Group, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on SELLAS Life Sciences Group, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about SELLAS Life Sciences Group, Inc. (SLS) by visiting AAII Stock Evaluator.

Relative Price Strength of SELLAS Life Sciences Group, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, SELLAS Life Sciences Group, Inc. has a weighted four-quarter relative price strength of 1.34%, which translates to a Momentum Score of 64 and is considered to be Strong.

Want to learn more about how SELLAS Life Sciences Group, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

SELLAS Life Sciences Group, Inc. Stock Price: Bottom Line

As of November 28, 2025, SELLAS Life Sciences Group, Inc.’s stock price is $1.620, which is up 10.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like SELLAS Life Sciences Group, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.